Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Avacc 10
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Intravacc Reports Positive Data for First-In-Human Intranasal SARS-CoV-2 Vaccine
Details : Avacc 10 consists of Outer Membrane Vesicles (OMV) from N. meningitidis mixed with the stabilized spike protein of SARS-CoV-2. It is an intranasal booster vaccine to prevent COVID-19.
Brand Name : Avacc 10
Molecule Type : Vaccine
Upfront Cash : Not Applicable
March 26, 2024
Lead Product(s) : Avacc 10
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Avacc 11
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : CARB-X
Deal Size : $0.6 million
Deal Type : Funding
Intravacc Receives US$ 633K CARB-X Funding for Gonorrhea Vaccine Development
Details : The proceeds will fund Avacc 11, a vaccine against Neisseria gonorrhoeae, using Intravacc’s outer membrane vesicle (OMV) platform technology.
Brand Name : Avacc 11
Molecule Type : Vaccine
Upfront Cash : Undisclosed
January 16, 2024
Lead Product(s) : Avacc 11
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : CARB-X
Deal Size : $0.6 million
Deal Type : Funding
Lead Product(s) : Gonorrhea Vaccine Avacc 11
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Avacc 11 (gonorrhea vaccine avacc 11) is the prophylactic intranasal gonorrhea candidate vaccine, consisting of outer membrane vesicles and microsphere encapsulated interleukin-12 induced Th1-driven immunity, with circulating and genital antibodies to Ne...
Brand Name : Avacc 11
Molecule Type : Vaccine
Upfront Cash : Not Applicable
January 16, 2023
Lead Product(s) : Gonorrhea Vaccine Avacc 11
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Avacc 10
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The phase I clinical trial has just commenced in a clinical center in Australia, and will assess the tolerability, safety and immunogenicity of the intranasal Avacc 10® vaccine. Avacc 10® is based on Intravacc's proprietary outer membrane vesicles (OMV...
Brand Name : Avacc 10
Molecule Type : Vaccine
Upfront Cash : Not Applicable
November 30, 2022
Lead Product(s) : Avacc 10
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Avacc 101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : EpiVax
Deal Size : $4.8 million
Deal Type : Collaboration
EpiVax Joins Intravacc, CEPI On Project To Develop Universal Betacoronavirus Vaccine
Details : Avacc 101 is Intravacc subunit betacoronavirus vaccine candidate. Avacc 101 vaccine candidate will be designed to provide broad protection against SARS-CoV-1, SAR-CoV-2, and MERS-CoV.
Brand Name : Avacc 101
Molecule Type : Vaccine
Upfront Cash : Undisclosed
November 01, 2022
Lead Product(s) : Avacc 101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : EpiVax
Deal Size : $4.8 million
Deal Type : Collaboration
Lead Product(s) : Avacc 101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : CEPI
Deal Size : $4.8 million
Deal Type : Funding
CEPI Partners With Intravacc To Develop An Intranasal, Broadly Protective Betacoronavirus Vaccine
Details : CEPI’s funding will support preclinical development and testing of Intravacc’s subunit vaccine candidate Avacc 101, which is based on its Outer Membrane Vesicle (OMV) platform.
Brand Name : Avacc 101
Molecule Type : Vaccine
Upfront Cash : Undisclosed
October 06, 2022
Lead Product(s) : Avacc 101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : CEPI
Deal Size : $4.8 million
Deal Type : Funding
Lead Product(s) : Recombinant Human IL-12
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : $14.6 million
Deal Type : Funding
Intravacc Awarded US$14.6 Million NIH/NIAID Contract To Develop Intranasal Gonorrhea Vaccine
Details : The grant will support the NG vaccine, called NGoXIM, based on gonococcal OMVs combined with sustained-release microspheres containing recombinant human IL-12, and will be administered intranasally.
Brand Name : NGoXIM
Molecule Type : Vaccine
Upfront Cash : Undisclosed
October 05, 2022
Lead Product(s) : Recombinant Human IL-12
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : $14.6 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : European Union
Deal Size : $2.5 million
Deal Type : Funding
DZNE and Intravacc Awarded EU Funding to Develop Vaccine Against Genetic ALS Variant
Details : DZNE developed an experimental vaccine that instructs the immune system to produce antibodies against these harmful poly-GA molecules. In a mouse model, this reduces poly-GA aggregates and largely prevents motor deficits.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
July 06, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : European Union
Deal Size : $2.5 million
Deal Type : Funding
Lead Product(s) : Avacc-3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Beijing Zhifei Lvzhu Biopharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Both parties will continue to collaborate to tailor the Avacc 3 concept vaccine for the respective territories, including upscaling, toxicology and clinical trials. Avacc 3 has significant advantages over existing whooping cough vaccines.
Brand Name : Avacc-3
Molecule Type : Vaccine
Upfront Cash : Undisclosed
May 02, 2022
Lead Product(s) : Avacc-3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Beijing Zhifei Lvzhu Biopharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : SF2a-TT15
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Institut Pasteur
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The results of the first-in-human trial for the SF2a-TT15, semi-synthetic glycan-based conjugate vaccine candidate against Shigella flexneri 2a, developed at the Institut Pasteur demonstrated safety and immunogenicity.
Brand Name : SF2a-TT15
Molecule Type : Vaccine
Upfront Cash : Not Applicable
March 22, 2022
Lead Product(s) : SF2a-TT15
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Institut Pasteur
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?